SUMMARY The prevalence of deoxyribonucleic acid (DNA) aneuploidy in 297 samples from 38 patients with ulcerative colitis of varying duration was investigated by flow cytometry. In 12 patients colitis was complicated by the development of colorectal carcinoma: one had three synchronous carcinomas. Only four of 14 carcinomas were DNA aneuploid. Deoxyribonucleic acid aneuploidy occurred focally in the colorectal mucosa in the presence and absence of carcinoma: rates of aneuploidy (67% in cancer patients and 42% in non-cancer patients), were not significantly different (x2= 1 0962, p=0295). A higher rate of DNA aneuploidy was found in dysplastic tissues (21%) compared with non-dysplastic tissues (15%), but again these differences did not reach statistical significance (X2=1 0747, p=0.299). Deoxyribonucleic acid aneuploidy and dysplastic change occurred more often with increasing duration of ulcerative colitis (p<0-001, p<0005 respectively). We conclude that flow cytometric analysis of cellular DNA content should not replace present morphological methods of assessment of premalignancy in ulcerative colitis, but may be a useful adjunct in the identification of abnormal mucosa.
The risk of carcinoma complicating ulcerative colitis was previously held to be substantial. 1-3 More recent work, however, suggests a lower incidence of malignant change in the overall colitic population. 4 To avoid unwarranted surgery, colonoscopic surveillance for dysplastic change is of value,5 6 but the criteria for determining cancer risk remain unsatisfactory. four of eight DNA aneuploid cancer colons showed more than one stem line and this was unrelated to the ploidy of the carcinoma. It is of note that the same or similar abnormal stem line (as defined by the same diploid index, DI ±0.2) appeared in widely separate areas of the colorectum in individual patients. This feature was apparent in 10/24 patients from both the cancer and long duration disease groups. Three carcinomas showed heterogeneity of DNA content.
Discussion
The assessment of 'premalignancy' and cancer risk in ulcerative colitis, using current criteria7 is highly subjective. Flow cytometry provides rapid, quantitative and reproducible measurements of DNA ploidy. A recent study has described DNA aneuploidy occurring in ulcerative colitis'6 but the prospective nature and design of the investigation limit full assessment of its value in cancer surveillance. Using a technique that enables us to examine paraffin embedded tissue, we have been able to retrospectively select groups of patients with ulcerative colitis, who are fully documented histologically and who also have a known clinical outcome.
It is of interest that only 29% of carcinomas complicating ulcerative colitis showed DNA aneuploidy compared with 60% of colorectal carcinomas arising in the general population measured under the same conditions in parallel studies (Quirke, unpublished observations The significance of DNA aneuploidy and its relationship to the development of cancer remains to be fully established. Certainly the finding of DNA aneuploidy in a colorectal biopsy would have no predictive value in deciding whether or not a patient has concurrent carcinoma elsewhere in the bowel. It may, however, be an indicator of future malignant change and this will be evaluated in our prospective series. Even if DNA aneuploidy is found to be predictive, however, the development of diploid carcinomas could not be anticipated by our present methods of flow cytometric DNA analysis. Although flow cytometric analysis may assist in the identification of abnormal mucosa, it would appear that the histological recognition of high grade dysplasia, even with its difficulties and limitations remains the most useful investigation in the routine surveillance of patients with ulcerative colitis.
